Medicine and Dentistry
Oncology
100%
Cardiovascular System
65%
Cardiotoxicity
51%
Radiation Therapy
50%
Cancer Therapy
47%
Heart Amyloidosis
46%
Malignant Neoplasm
41%
Cardiovascular Disease
40%
Congestive Heart Failure
36%
Lung Cancer
34%
Heart Graft
32%
Coronary Artery Calcium
31%
Meta-Analysis
29%
Diseases
28%
Cardiovascular Toxicity
28%
Systematic Review
27%
Venous Thromboembolism
27%
Biological Marker
27%
Transthyretin
23%
Infection
22%
Apoplexy
22%
Heart Transplantation
22%
Myocardial Infarction
22%
Atrial Fibrillation
21%
Coronary Artery Disease
21%
COVID-19
19%
Cohort Analysis
19%
Risk Stratification
19%
Patient Care
18%
Heart Disease
18%
Observational Study
18%
Cancer
18%
Odds Ratio
17%
Amyloidosis
17%
Hospital Mortality
14%
Light Chain
13%
Cardiovascular Risk
13%
Clinical Trial
12%
Immunosuppressive Treatment
12%
Pressure Control
12%
Blood Pressure
12%
Statin
12%
Breast Cancer
12%
Amyloid Protein
12%
Cancer Types
11%
End Stage Renal Disease
11%
Retrospective Cohort Study
11%
Atherosclerosis
11%
Overall Survival
10%
Left Ventricular Assist Device
10%
Keyphrases
Cardio-oncology
87%
Coronary Artery Calcium
52%
Meta-analysis
48%
Cardiac Amyloidosis
46%
Systematic Meta-analysis
46%
Cancer Therapy
37%
Confidence Interval
34%
Cardiovascular Toxicity
34%
Radiation Therapy
33%
Radiation-induced Heart Disease
32%
Heart Failure
32%
Lung Cancer
30%
Major Adverse Cardiovascular Events
30%
Cardiotoxicity
28%
In Cancer
25%
COVID-19
24%
In-hospital Mortality
23%
Cancer Patients
23%
Myocardial Infarction
22%
Cardiac Transplant Recipients
22%
Venous Thromboembolism
22%
Cardiovascular Disease
21%
Radiation-induced Cardiotoxicity
21%
Cardiovascular Risk Assessment
20%
Atrial Fibrillation
20%
Risk Stratification
20%
Patient Management
19%
Hospitalization
19%
Coronary Artery Calcium Score
18%
Amyloidosis
18%
Risk of Death
18%
Long-run Risk
18%
Early Detection
18%
Transthyretin Amyloidosis
18%
Venous Thromboembolism Prophylaxis
18%
All-cause Mortality
18%
Heart Transplantation
17%
Patients with Cancer
17%
Older Adults
17%
Atherosclerotic Cardiovascular Disease (ASCVD)
16%
Malignancy
16%
Comorbidity
16%
Cardiac Dysfunction
15%
Improved Survival
15%
High Risk
15%
Cardiac Substructures
15%
Risk Factors
15%
Hypertension
15%
Heart Failure with Preserved Ejection Fraction (HFpEF)
13%
Consensus Statement
13%